Ambroxol - ALZFORUM
Ambroxol is a mucolytic compound and the main ingredient of over-the-counter cough medicines sold in many countries. Syrup, tablet, and other forms are used at doses of 30 to 120 mg per day to reduce or thin mucous secretions and ease sore …
Ambroxol Hydrochloride Improves Motor Functions and Extends
Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Front Pharmacol. 2019;10:883. Epub 2019 Aug 7 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.
Early initiation of ambroxol treatment diminishes neurological ...
Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings. Eur J Paediatr Neurol. 2021 May;32:66-72. Epub 2021 Mar 31 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or ...
Therapeutics | ALZFORUM
2015年11月25日 · Therapeutics. This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at [email protected].
TDP-43 (Q331K) - ALZFORUM
2018年3月6日 · Consistent with TDP-43 autoregulation, a decrease in endogenous murine levels was observed in transgenic mice. Transgene expression was highest in the brain and spinal cord with very low levels observed in other tissues. At birth, the TDP-43 Q331K mice were indistinguishable from non-Tg littermates. Tremor was observed as early as three to four ...
Large Phase 2 Trial Starting Up in Genetic Parkinson’s Population
2014年6月13日 · A Phase 2 trial has been approved by the Food and Drug Administration and will begin enrolling this month, with completion scheduled for 2022, Sardi said. The study will enroll about 230 people who have Parkinson’s and a GBA mutation. Although this initial trial only includes mutation carriers, the researchers believe the strategy may work to ...
Parkinson’s Treatments Go After Genetic Targets | ALZFORUM
Ambroxol is in Phase 2 PD trials in Canada and London, with a Phase 1 trial starting in Florida. Schapira led the London trial, AIM-PD, which enrolled 12 GBA carriers and 10 people with idiopathic PD to look at safety and establish proof of principle. Participants took 1,200 mg/day of Ambroxol for six months.
Research Models | ALZFORUM
2024年8月1日 · SORL1 knockout, knockin, and transgenic mice are now in the Research Models database. The database will be updated as more models become available. This database provides information about selected rodent models of neurodegenerative disease, including Alzheimer’s, Parkinson’s, and ALS. By summarizing, visualizing, and continuously updating ...
Venglustat - ALZFORUM
2021年2月5日 · Venglustat is a brain-penetrant allosteric inhibitor of the enzyme glucosylceramide synthase. GCS catalyzes an early step in the synthesis of many glycolipids. Venglustat is being developed for lysosomal storage diseases, including Gaucher’s, Fabry, and for Parkinson’s caused by mutations in the GBA1 gene.
Therapeutics Search - ALZFORUM
Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABBV-CLS-7262 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24.060 ACI-3024 ACI-35 ACI-7104.056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AIT-101 AKST4290 AL002 AL003 AL044 AL101 …